Preventing The Transition From Acute To Chronic Pain. The Role Of Neural And Non-neural Factors.
Funder
National Health and Medical Research Council
Funding Amount
$2,998,900.00
Summary
Pain following injury usually dissipates as the injury heals, however in some individuals it persists and lasts for years. Chronic pain is extremely difficult to treat, particularly that which originates from a damaged nerve. One of the roadblocks in developing effective treatments is our limited understanding of the pathophysiology. The overall aim of this proposal is to address this gap and determine the processes that occur in the brain that results in acute pain transitioning to chronic.
Betacellulin: Defining A Novel Sub-type In Schizophrenia
Funder
National Health and Medical Research Council
Funding Amount
$907,515.00
Summary
Schizophrenia is a severe lifelong mental disorder affecting 0.7% of the world population with only partially effective symptomatic treatments. Its cause is unknown and thus cures cannot be developed currently. A promising candidate is betacellulin a growth factor which is very reduced in the brain and blood of people with schizophrenia. Little is known about its role in the brain and this project seeks to identify its relevance to schizophrenia as a step to develop new treatments.
Understanding Sex Differences In Alcohol Use Disorder: The Role Of Stress And Neuropeptides
Funder
National Health and Medical Research Council
Funding Amount
$692,106.00
Summary
Alcohol use disorders (AUD) are an emerging issue in women, yet there is little understanding of the how the male and female brains differ in response to excessive alcohol consumption. In pilot studies, we have found that deletion of a specific brain chemical causes differences in the way male and female mice consume alcohol in excess. We will further characterise this system and test new approaches to reduce the desire to consume alcohol.
Vascular Changes Are A Key Contributor To And Novel Drug Target For Interferon-alpha Induced Neurological Disease
Funder
National Health and Medical Research Council
Funding Amount
$1,245,401.00
Summary
Type I interferons (IFN-Is) contribute to wide range of neurological diseases including ageing and neurodegeneration. At its extreme IFN-I-mediated neurodegeneration is known as 'interferonopathy'. The mechanisms of how IFN-Is drive disease are unclear, making causal treatment difficult. We have recently uncovered ground-breaking evidence that abnormal blood vessels are a key contributor to the disease. Here, we will investigate novel treatment targets for patients with interferonopathies.
Discovering How A Novel Anti-malarial Drug Series Rapidly Kills Parasites
Funder
National Health and Medical Research Council
Funding Amount
$672,971.00
Summary
We have developed a new set of highly potent anti-malarial drugs but we do not know how they work. Identifying how these compounds work is important for improving their effectiveness and safety. We will discover how these drugs kill parasites by using a number of cutting edge methods that could also be useful for discovering how other drugs work. Data generated will progress these compounds along the drug development pipeline which urgently needs a constant supply of new antimalarials.
Understanding How The E3 Ubiquitin Ligase Parkin Dictates Neuronal Survival
Funder
National Health and Medical Research Council
Funding Amount
$947,560.00
Summary
Parkinson's disease is the fastest-growing neurodegenerative disorder, and the second most common neurodegenerative disease after Alzheimer's disease. The disease arises due to the loss of specific neurons in the brain that control motor function. We aim to understand what triggers these neurons to die and to resolve how inflammation promotes disease. This information will underpin the development of the first, and much needed, drugs that slow or stop Parkinson's disease progression.
A Practice Change For Patients With Severe Chronic, Clinically Unexplained Gastrointestinal Symptoms: A Randomised, Controlled Intervention To Assess Efficacy And Cost-effectiveness
Funder
National Health and Medical Research Council
Funding Amount
$1,276,080.00
Summary
Unexplained chronic gastrointestinal symptoms are extremely common and costly to the health system. Currently patients are managed in the hospital setting with the 'typical' face-to-face office-based model which sees the clinician spending valuable time gathering information and often treatments (e.g. allied health) delivered in a non-standard way. This project will evaluate the effectiveness of a new standard best-practice clinical model with a structured technology enabled management approach.
We aim to discover and develop a blood test that can predict which lung cancers have spread to lymph glands in the chest, to help decide on the best treatment options.
Evidence For Action On Cold, Damp And Mould In Australian Homes
Funder
National Health and Medical Research Council
Funding Amount
$955,649.00
Summary
We know that living in cold and damp homes is bad for people's health. Surprisingly in Australia we do not know how much exposure to poor conditions and financial hardship combines to generate poor health at the population level. We will quantify this impact and estimate the benefit of interventions (such as mould removal and assistance for paying utility bills). This project will provide governments with evidence for tackling this housing-related health problem.
Preservation And Generation Of Beta Cells In Type 1 Diabetes With Novel Mimetic Peptides
Funder
National Health and Medical Research Council
Funding Amount
$1,096,055.00
Summary
Type 1 diabetes (T1D) is an autoimmune disease that destroys insulin producing beta cells in the pancreas. It can cause heart and kidney disease, and nerve damage. T1D is treated with insulin injections that can cause life-threatening low blood sugar levels. We have developed a new treatment that may stop beta cell loss, generate new beta cells and remove the need for insulin injections in T1D patients. A positive outcome will identify a completely new T1D treatment option.